

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
24 December 2003 (24.12.2003)

PCT

(10) International Publication Number  
**WO 03/105763 A2**


- (51) International Patent Classification<sup>7</sup>: **A61K**
- (21) International Application Number: **PCT/US03/18657**
- (22) International Filing Date: **13 June 2003 (13.06.2003)**
- (25) Filing Language: **English**
- (26) Publication Language: **English**
- (30) Priority Data:  
**60/388,930 14 June 2002 (14.06.2002) US**
- (71) Applicant (for all designated States except US): **AMYLIN PHARMACEUTICALS, INC. [US/US]; 9373 Towne Center Drive, San Diego, CA 92121 (US).**
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): **GEDULIN, Bronislava [US/US]; 14174 Half Moon Bay Drive, Del Mar, CA 92014 (US). YOUNG, Andrew, A. [NZ/US]; 1887**

- Caminito Velasco, La Jolla, CA 92037 (US). **PATERNITI, James, R. Jr. [US/US]; 19833 Birch Bluff Avenue, San Diego, CA 92131 (US).**
- (74) Agent: **PERKINS COIE LLP; WISE, Michael J., CANDELORO, Carlos, Patent-LA, P.O. Box 1208, Seattle, WA 98111-1208 (US).**
- (81) Designated States (national): **AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.**
- (84) Designated States (regional): **ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),**

[Continued on next page]

(54) Title: **PREVENTION AND/OR TREATMENT OF INFLAMMATORY BOWEL DISEASE USING PYY OR AGONISTS THEREOF**

**Spleen Weight**



**(57) Abstract:** A novel use of PYY or a PYY agonist is disclosed for treating a bowel condition such as inflammatory bowel disease (e.g. ulcerative colitis and Crohn's disease), bowel atrophy, loss of bowel mucosa and loss of bowel mucosal function. The novel use is based on the discovery and demonstration that administration of PYY or a PYY agonist to an animal can protect the colon from injury induced by a hapten known to induce colitis.

WO 03/105763 A2